Certara Inc (NASDAQ:CERT), a leader in biosimulation software and services for drug development, reported its fourth quarter and full-year 2025 financial results, delivering a mixed performance against analyst expectations and providing a cautious outlook for the year ahead. The market's initial reaction, reflected in pre-market trading, was negative.
Earnings and Revenue Versus Estimates
The company's results for the final quarter of 2025 came in slightly below Wall Street's forecasts on key profitability metrics, while revenue was marginally lower than anticipated.
- Q4 2025 Revenue: Reported at $103.6 million, representing a 3% year-over-year increase. This figure fell short of the analyst consensus estimate of approximately $105.3 million.
- Q4 2025 Adjusted EPS: Came in at $0.09 per share. This missed the analyst estimate of $0.11 per share.
For the full fiscal year 2025, the company reported revenue of $418.8 million, a 9% increase from the prior year, and adjusted EBITDA of $134.5 million, up 10%.
Market Reaction and Guidance
The pre-market decline in the stock price suggests investor disappointment, likely tied to the earnings miss and the company's tempered guidance for 2026. Certara's outlook for the coming year points to a period of transition and investment under new leadership.
The company's provided full-year 2026 guidance is as follows:
- Revenue growth of 0% to 4%.
- Adjusted EBITDA margin of 30% to 32%.
- Adjusted diluted earnings per share in the range of $0.44 to $0.48.
This guidance appears conservative when compared to existing analyst expectations, which had projected sales of approximately $453.6 million for FY 2026. The company's revenue growth range implies a top-line figure between roughly $418.8 million and $435.6 million, situating the high end below current analyst forecasts. Similarly, the EPS guidance midpoint of $0.46 is below the implied run rate from the Q4 result.
Quarterly Performance and Strategic Highlights
The fourth quarter revealed a divergence between the company's software and services segments. Software revenue grew 10% year-over-year to $46.4 million, driven by biosimulation products. Conversely, services revenue saw a slight decline of 1% to $57.3 million, which the company attributed to normal seasonal fluctuations. Importantly, total bookings for the quarter increased 7% to $155.2 million, with services bookings jumping 17%, potentially signaling future revenue strength.
A significant development was the appointment of Jon Resnick as Chief Executive Officer, effective January 1, 2026. In the earnings release, Resnick characterized 2026 as "a year of transition and investment," focused on sharpening strategy, accelerating innovation, and improving commercial execution to position the company for sustainable long-term growth.
Chief Financial Officer John Gallagher noted that full-year and fourth-quarter revenue met internal expectations and that the company ended the year at the high end of its adjusted EBITDA margin plan. He stated the company expects stable end markets in 2026 and initiatives to "drive improving revenue growth through the year."
Conclusion
Certara's Q4 earnings presented a classic "beat and raise" scenario in reverse, with results missing estimates and forward guidance falling shy of Wall Street's expectations. The market's negative reaction underscores concerns about near-term growth deceleration as the company undergoes a strategic transition under new leadership. While strong bookings and a robust full-year 2025 performance provide a solid foundation, the focus for investors will be on the execution of Certara's refreshed strategy throughout 2026 to reignite growth momentum.
For a detailed look at upcoming earnings dates and analyst estimate revisions, you can review Certara's earnings and estimates page here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor does it recommend buying or selling any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.